|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2009-8-12
|
|
pubmed:abstractText |
Synovial sarcoma (SyS) occurs mostly in young adults and is characterized by an aggressive course. Combined treatment including chemotherapy, radiotherapy and surgical excision of the tumour is still not satisfactory, with mean 5-year survival of 30-50%. New targeted treatment options have appeared recently, e.g. HER2 and EGFR antagonists. Initial studies have revealed immunohistochemical overexpression of the EGFR in SyS; therefore trials with EGFR antagonist therapy have commenced. The aim of our study was to evaluate the status of HER2, EGFR and TOPIIA in SyS before and after combined therapy. Immunohistochemistry and FISH tests were performed. Significant discrepancies between protein expression and gene status were found. The authors discuss the potential reasons for that phenomenon.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/DNA Topoisomerases, Type II,
http://linkedlifedata.com/resource/pubmed/chemical/DNA topoisomerase II beta,
http://linkedlifedata.com/resource/pubmed/chemical/DNA-Binding Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/EGFR protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/HER2 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Ifosfamide,
http://linkedlifedata.com/resource/pubmed/chemical/Receptor, Epidermal Growth Factor,
http://linkedlifedata.com/resource/pubmed/chemical/Receptor, erbB-2
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
1233-9687
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
60
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
10-8
|
|
pubmed:dateRevised |
2009-11-19
|
|
pubmed:meshHeading |
pubmed-meshheading:19670699-Adolescent,
pubmed-meshheading:19670699-Adult,
pubmed-meshheading:19670699-Antineoplastic Agents,
pubmed-meshheading:19670699-Combined Modality Therapy,
pubmed-meshheading:19670699-DNA Topoisomerases, Type II,
pubmed-meshheading:19670699-DNA-Binding Proteins,
pubmed-meshheading:19670699-Female,
pubmed-meshheading:19670699-Gene Amplification,
pubmed-meshheading:19670699-Gene Expression Regulation, Neoplastic,
pubmed-meshheading:19670699-Humans,
pubmed-meshheading:19670699-Ifosfamide,
pubmed-meshheading:19670699-Male,
pubmed-meshheading:19670699-Middle Aged,
pubmed-meshheading:19670699-Radiotherapy,
pubmed-meshheading:19670699-Receptor, Epidermal Growth Factor,
pubmed-meshheading:19670699-Receptor, erbB-2,
pubmed-meshheading:19670699-Sarcoma, Synovial,
pubmed-meshheading:19670699-Soft Tissue Neoplasms,
pubmed-meshheading:19670699-Young Adult
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Her2, EGFR and TOPIIA gene amplification and protein expression in synovial sarcoma before and after combined treatment.
|
|
pubmed:affiliation |
Department of Pathology, Maria Sk?odowska-Curie Memorial Cancer Centre and Institute of Oncology, Warsaw.
|
|
pubmed:publicationType |
Journal Article,
Comparative Study
|
